Mylan Executive Chairman Robert Coury is telling Teva Pharmaceutical Industries to “stop playing games with our company” in a strongly worded letter released Monday.
Teva said back in April it wanted to make a $40 billion bid to acquire the generic pharmaceutical company that is run out of Washington County. The bid was rejected by Mylan’s board — and Coury in a strongly worded responses — but Teva has kept interest even as Mylan pursues its own unsolicited bid for another generic pharmaceutical company, Perrigo plc.
Coury wrote that without “an actual offer” or the timing, Teva should provide “unequivocal clarification” about what it wants to do with Mylan. The letter was sent to Teva’s CEO and also filed with the SEC.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI